Printer Friendly

Immunomedics awarded patent for humanized carcinoembryonic antigen antibody.

Immunomedics, Inc. (Morris Plains, NJ) reported the issuance of United States Patent 6,676,924, covering a specific humanized antibody to carcinoembryonic antigen (CEA) that is attached to a therapeutic agent. The therapeutic is a cytotoxic drug or isotope, or an immunomodulator. In addition, the patent claims include this humanized antibody conjugated with a diagnostic, such as an imaging agent. This patent is an extension of United States Patent 5,874,540, which issued to the company in 1994.

"CEA is one of the most prevalent cancer markers known and comprises one of the most frequently tested substances shed from the tumor into the blood in a variety of cancer patients, such as those with colorectal and breast cancer," commented Cynthia L. Sullivan, President and Chief Executive Officer of Immunomedics.

Ms. Sullivan added: "Our company has been a leader in CEA research and is testing this humanized antibody, alone (unconjugated) as well as conjugated with radioisotopes (iodine-131 and yttrium-90) in several Phase I and II clinical trials involving patients with colorectal, pancreatic and breast cancer, with encouraging safety and activity observed." "This new patent

now strengthens our intellectual property in the therapeutic and diagnostic areas involving CEA," remarked Ms. Sullivan.

Immunomedics develops diagnostic imaging and therapeutic products for the detection and treatment of cancer and other serious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and other sites of disease. Immunomedics has nine therapeutic product candidates in clinical or near clinical development and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide (epratuzumab), for which certain Phase II clinical trials for the treatment of non-Hodgkin's lymphoma have already been completed, and CEA-Cide (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.

Immunomedics, Inc.

+1-973-605-8200

www.Immunomedics.com
COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Immunomedics, Inc.
Comment:Immunomedics awarded patent for humanized carcinoembryonic antigen antibody.(Immunomedics, Inc.)
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Feb 1, 2004
Words:313
Previous Article:Neurogen, Merck agreement for pain drugs cleared.
Next Article:Former Vertex patent counsel sentenced to prison for insider trading.
Topics:


Related Articles
Amgen licenses late-stage lymphoma therapeutic from Immunomedics.
Immunomedics awarded patent for infectious disease therapy.
Patented method could overcome drug resistance in cancer.
Immunomedics to appeal tumor detection patent infringement decision.
Cytogen granted summary judgment of non-infringement of prostate cancer patent.
Alfacell announces new research collaboration to develop next-generation targeted therapies for cancer.
Lpath granted patent protection for anti-cancer anti-S1P antibody.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters